Natco Pharma
VC Fund
Hyderabad, India
Natco Pharma is a manufacture and market affordable medicines that comply with global standards and to achieve market leadership in domestic as well as international markets.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Natco Pharma invests in
Stages Natco Pharma invests in
Countries Natco Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rajeev Nannapaneni
|
|||
|
Appa Rao S V V N
|
|||
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 2 (33%)
- Fitness 1 (17%)
- Medical 1 (17%)
- Genetics 1 (17%)
Stage
- Series B 2 (33%)
- Series A 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
- Corporate Round 1 (17%)
Country
- India 4 (67%)
- United States 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Rajeev Nannapaneni
Vice Chairman and CEO
|
Vice Chairman and CEO | Total investments: 1 | Find email | |
|
Appa Rao S V V N
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EGenesis
|
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M / Series D / Sep 04, 2024 | |
Cellogen Therapeutics
|
Cellogen Therapeutics is a biotech company that is currently working on developing revolutionary cell therapy-based solutions. It treats a variety of hematological malignancies, solid tumors, and hemoglobinopathies using modern cellular engineering tools and gene therapy. | $1.8M / Corporate Round / Jan 17, 2024 | |
Pee Safe
|
Pee Safe was started in 2013, launching the first of its kind toilet seat sanitizer. Since 2017, the company has expanded into several personal hygiene categories including feminine hygiene (pads, tampons, cups, etc), men's intimate hygiene, hand hygiene (Palm Safe), face mask and mist (Pollution Safe), while being one of the leaders in a fewsub-categories. | $3M / Series B / Sep 11, 2023 | |
Eyestem
|
Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treatincurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety. | $6.4M / Series A / Aug 08, 2022 | |
CION Cancer Clinics
|
CION Cancer Clinics operates a distributed network of day-care cancer treatment centers. | $1.5M / Mar 24, 2021 | |
|
Eyestem
|
Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treatincurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety. | $10M / Series B |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Natco Pharma invest in?
Natco Pharma invests primarily in Health Care, Biotechnology and Fitness startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Natco Pharma?
Public channels for Natco Pharma include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Natco Pharma?
The team at Natco Pharma includes Rajeev Nannapaneni (Vice Chairman and CEO) and Appa Rao S V V N (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
